CDC7 kinase inhibitors and uses thereof
The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
1. A method for treating cancer in a human subject in need thereof, comprising administering to the human subject a therapeutically effective amount of a compound of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein the cancer is a solid tumor.
2. The method of claim 1 , wherein the cancer comprises a genetic mutation.
3. The method of claim 2 , wherein the genetic mutation comprises a RAS mutation, an EGFR mutation, a KRAS mutation, a p53 mutation, a BRAF mutation, a EVI1 mutation, a Flt-3 mutation, WT-1 mutation, a cyclin D mutation, a PTEN mutation, an ABL kinase mutation, or a chromosomal abnormality.
4. The method of claim 1 , wherein the cancer is a multi-drug resistant (MDR) cancer.
5. The method of claim 1 , wherein the cancer is relapsed and/or refractory cancer.
6. The method of claim 1 , further comprising administering at least one other therapy or therapeutic agent.
7. The method of claim 6 , wherein the at least one other therapy is radiation.
8. The method of claim 1 , wherein the compound is administered by systemic intravenous injection in a bolus or continuous infusion regimen.
9. A method for treating cancer in a human subject in need thereof comprising administering to the human subject a therapeutically effective amount of a compound of the Formula (II):
or a pharmaceutically acceptable salt thereof, wherein the cancer is prostate cancer, renal cell carcinoma, cervical cancer, glioblastoma, retinoblastoma, rhabdomyosarcoma, desmoplastic small round cell tumor, breast cancer, mesothelioma, or Ewing's sarcoma.
10. The method of claim 9 , wherein the cancer comprises a genetic mutation.
11. The method of claim 10 , wherein the genetic mutation comprises a RAS mutation, an EGFR mutation, a KRAS mutation, a p53 mutation, a BRAF mutation, a EVI1 mutation, a Flt-3 mutation, WT-1 mutation, a cyclin D mutation, a PTEN mutation, an ABL kinase mutation, or a chromosomal abnormality.
12. The method of claim 9 , wherein the cancer is a multi-drug resistant (MDR) cancer.
13. The method of claim 9 , wherein the cancer is a relapsed and/or refractory cancer.
14. The method of claim 9 , further comprising administering at least one other therapy or therapeutic agent.
15. The method of claim 14 , wherein the at least one other therapy is radiation.
16. The method according to claim 9 , wherein the compound is administered by systemic intravenous injection in a bolus or continuous infusion regimen.